Documente Academic
Documente Profesional
Documente Cultură
SCLERODERMIA
Factorii de risc :
Genetici :
-RR al rudelor de gradul I crescut pentru SS (RR =13) sau alte boli
autoimune (LES,PR)
-Asociere slaba cu genele HLA
Factorii de mediu -Infectiosi : CMV
-Noninfectiosi : produse petroliere (toluen, tricloretilen),
clorura de polivinil , L-triptofan, silicon, medicamente ( bleomicina,
pentazocina, cocaina, unele anorexigene
1
Patogenie : inflamatie si autoimunitate:
Afectarea /lezarea endoteliului vascular este momentul initial in
patogeneza SS
Factorii trigger posibili : factori serici citotoxici (radicalii de oxigen?),
enzime proteolitice (?), autoanticorpi anti celula endoteliala (?),virusuri
vasculotrope (?), citokinele inflamatorii (?), factorii de mediu (?)
Patogenie : activarea sistemului imun
Limfocitele T: infiltrate limfocitare perivasculare in fazele precoce ale
bolii (CD4 in piele, CD8 in plaman)->Prezenta infiltratelor cu celule T cu
profil secretor de tip TH2 si actiune profibrotica: IL4, IL5 , IL13, IL6
Activarea monocitelo/macrofagelor cu secretia de citokine
proinflamatorii (IL1,TNFalfa) si profibrotice ( IL6, TGF-beta)
Limfocitele B :Productie de autoanticorpi, IL6
Patogenie : vasculopatia proliferativ/obliterativa
Cresterea reactivitatii vasculare prin injuria endoteliului vascular cu
dereglarea productiei de substante vasodilatatoare (prostaciclina, oxidul
nitric) si vasoconstrictoare (endotelina-1)
Agregare plachetara : tromboze intravasculare , eliberare de substante
vasoconstrictoare (tromboxan)
Remodelare vasculara : proliferarea intimei si a mediei, fibroza
adventicei
Patogenie : vasculopatia:
Ingustarea lumenului vascular :
-Vasoconstrictie, ischemie de reperfuzie
-Remodelare vasculara : proliferarea intimei, fibroza adventicei
-Tromboze intravasculare
Obliterare vasculara si hipoxie tisulara
2
Morfopatologie : -leziunile morfopatologice sunt prezente in:
Piele
Tractul GI : gura, esofag, stomac, intestin
Plaman
Rinichi
Inima
Alte organe :sinoviala, tecile tendoanelor, muschi, glanda tiroida,
glandele salivare
Clasificare :
1.Sclerodermia localizata
Morpheea
Lineara
In “lovitura de sabie”
2.Scleroza sistemica
Localizata : boala cutanata limitata (distal de coate si /sau genunchi)
Difuza : boala cutanata difuza
3
Sindromul Raynaud (mai ales in formele cutanate limitate)
Tumefierea difuza a mainilor, ingrosarea tegumentelor sau artrita in
formele de boala cu afectare difuza
Ocazional , afectarea viscerala : simptome esofagiene (disfagie,
pirozis) sau pulmonare (dispnee)
Sindromul Raynaud secundar SS :
-Vasculopatie obliterativa a vaselor mici ale membrelor +
vasospasm indus de frig
-Principala forma de debut in SS localizata (poate precede celelalte
simptome/semne cu luni sau ani)
-Evolutie fazica : paloare (vasospasm), cianoza (staza venoasa),
roseata (hiperemia si revenirea fluxului sanguin)
-Leziuni ireversibile : ulcere digitale, suprafetele de extensie a IPP,
MCP, stiloida ulnara, cot (ischemie + microtrumatism), gangrena (nu sunt
prezente in sindromul Raynaud primar)
-Poate precede alte manifestari clinice cu luni sau ani
Modificari ale pielii ( ingrosarea tegumentelor)
-edeme cu sau fara godeu ale degetelor, mainilor, antebratelor,
fetei, gambe, picioare (faza edematoasa)
-piele ingrosata si dura la degete, maini, fata +/- antebrate, brate,
piept, membre inferioare, abdomen (faza indurativa)
-telangiectazii (dilatatia vaselor din derm)
-calcinoza (calcificari cutanate sau subcutanate din hidroxiapatita)
-cicatrici ale pulpei degetelor, ulceratii, gangrene, mumificare,
amputare
Tractul gastrointestinal (prin dismotilitate determinata de atrofia si
fibroza musculaturii netede sau vasculopatie/GAVE : gastric antral vascular
ectasia)
-Gura : ingrosarea tegumentului perioral, reducerea aperturii orale, carii
dentare xerostomia
-Esofag : reflux, stricturi, metaplazia Barrett
-Stomac : gastropareza (satietate precoce), gastrita, ectazii vasculare antrale
-Intestinul subtire : hipomotilitate (borborigme, flatulenta),
staza, suprapopulare bacteriana (diaree, malabsorbtie), pseudo-obstructie,
pneumomatoza
-Colonul : hipomotilitate, pseudo-obstructie, pseudo-diverticuli
-Anus si rect : incompetenta sfincteriana
-Ficat : ciroza biliara primitiva
Manifestari clinice pulmonare :
4
-Fibroza pulmonara : dispnee, tuse seaca, modificari Rx, disfunctie
ventilatorie restrictiva, HRCT(85% din pacientii cu SS), DLCO, lavajul
bronhoalveolar
-Hipertensiunea pulmonara:DLCO (scadere izolata), ECO, cateterismul
cordului drept prin afectare:
>pulmonara : fibroza, vasculopatie sclerodermica
>cardiaca : disfunctie diastolica, boala valvulara, ICC
Manifestari
-Anti Topoisomerase-I : SS difuza, fibroza pulmonara, afectarea cardiaca,
criza renala sclerodermica
-Anti proteine ale centromerului :SS localizata, ischemia degetelor,
calcinoza, HTP izolata
-U3-RNP : dcSScPAH, ILD, scleroderma renal crisis, myositis
-Th/T0 : lcSScILD, PAH
-PM/Scl : lcSScCalcinosis, myositis
-U1-RNP : MCTD, PAH
-RNA polymerase III : dcSScExtensive skin, scleroderm
5
DISEASE CLASSIFICATION — Five major diffuse connective
tissue diseases (DCTD) exist according to current classification schema:
systemic lupus erythematosus (SLE); scleroderma (Scl); polymyositis (PM);
dermatomyositis (DM); and rheumatoid arthritis (RA). A sixth disorder,
Sjögren's syndrome, is commonly associated with each of these diseases, but
is called primary Sjögren's syndrome when it occurs alone.
The classical clinical descriptions of these disorders are well known
and most patients with well-differentiated disease are easily recognized.
However, experienced physicians often note that one DCTD seems to evolve
into another over the course of several years [5-10] . This occurs in about 25
percent of patients, who are then said to have an overlap syndrome [6] . (See
"Undifferentiated systemic rheumatic (connective tissue) diseases and
overlap syndromes").
(Definition and diagnosis of mixed connective tissue disease )
6
Patients with U1 RNP antibodies seldom develop diffuse proliferative
glomerulonephritis, psychosis, or seizures; these abnormalities are a major
source of morbidity and mortality in SLE [11,12] .
Patients with U1 RNP antibodies nearly always have an early
development of Raynaud phenomenon [1,2] and a nailfold capillary pattern
that is the same as in Scl but different from classical SLE [13] . The
Raynaud phenomenon only occurs in about 25 percent of patients with
classical SLE.
Patients with U1 RNP antibodies are more likely to develop
pulmonary hypertension than patients with classical SLE or Scl. Pulmonary
hypertension is the major cause of death in MCTD [14,15] .
Patients with U1 RNP antibodies are more likely than SLE patients to
be rheumatoid factor positive [2] and develop an erosive arthritis [3,16] .
Thus, the concept of MCTD is useful in defining a subgroup of
patients with unique clinical features, treatment profile, and prognosis.
Whether MCTD is a unique subset of SLE or Scl or is a distinct clinical
entity is not clinically so important.
7
presence of MCTD rather than another connective tissue disorder such as
SLE or Scl:
Raynaud's phenomenon and swollen hands or puffy fingers [7,8]
The absence of severe renal and central nervous system (CNS) disease
[2,9,10]
More severe arthritis and the insidious onset of pulmonary
hypertension (not related to lung fibrosis) differentiate MCTD from both
SLE and Scl [11,12]
Autoantibodies whose fine specificity is anti-U1 RNP, especially
antibodies to the 68 Kd protein [13] ( Clinical manifestations of mixed
connective tissue disease )